First-line treatment includes trastuzumab (Herceptin, Genentech) plus chemotherapy. Some patients also receive pembrolizumab (Keytruda, Merck). However, “most patients experience disease ...

1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

The new subcutaneous (injectable) formulation of Herceptin (trastuzumab) can be administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form. The European ...

Advancements in Genomics and AI Propel Patient-Centric Therapies Across Key Regions The global personalized medicine market ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...